GlassScriptPhysician profile
Gabrielle Scott
NPI 1457967614
$7,332.49
in general payments reported to CMS, 2019-2025
40 companies · $2,454 in 2025
The $2,454 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $984 · 2022: $701 · 2023: $1,423 · 2024: $1,770 · 2025: $2,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,498 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,497.56 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,567.12 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $842.62 | 2021-2025 | |
| Biogen, INC. | $831.22 | 2021-2025 | Tysabri, Vumerity, Spinraza |
| Ucb, INC. | $550.30 | 2021-2025 | Briviact, Nayzilam, Rystiggo |
| Pfizer INC. | $461.16 | 2023-2025 | |
| Amgen INC. | $273.46 | 2021-2025 | Uplizna, Aimovig |
| Sk Life Science, INC. | $263.18 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $243.02 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurelis, INC. | $208.57 | 2024-2025 | Valtoco |
| Janssen Pharmaceuticals, INC | $188.34 | 2021-2024 | Xarelto |
| Emd Serono, INC. | $177.54 | 2022-2025 | Mavenclad |
| Acadia Pharmaceuticals INC | $135.17 | 2021-2025 | Nuplazid, Daybue |
| Takeda Pharmaceuticals U.S.A., INC. | $128.20 | 2023-2025 | Hyqvia |
| Eisai INC. | $122.57 | 2025 | |
| Genentech USA, INC. | $113.70 | 2022-2025 | Ocrevus Zunovo, Ocrevus |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $108.55 | 2024-2025 | Ultomiris |
| Jazz Pharmaceuticals INC. | $105.37 | 2023-2025 | |
| Lundbeck LLC | $102.53 | 2022-2025 | Vyepti |
| Lilly USA, LLC | $82.85 | 2021-2024 | Reyvow, Emgality, Amyvid |
| Horizon Therapeutics Plc | $66.49 | 2022-2023 | Uplizna |
| Csl Behring | $62.77 | 2023-2024 | Hizentra |
| Otsuka America Pharmaceutical, INC. | $61.68 | 2023-2024 | Nuedexta |
| Biohaven Pharmaceutical Holding Company LTD. | $55.84 | 2022 | |
| Aquestive Therapeutics, INC. | $54.28 | 2021 | |
| Kyowa Kirin, INC. | $53.77 | 2021-2023 | Nourianz |
| Catalyst Pharmaceuticals, INC. | $50.36 | 2024-2025 | |
| Avanir Pharmaceuticals, INC. | $49.93 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $44.61 | 2023-2024 | Ztlido |
| Biohaven Pharmaceuticals, INC. | $42.33 | 2021 | |
| Acorda Therapeutics, INC | $41.81 | 2021-2023 | Ampyra, Inbrija |
| Argenx US, INC. | $37.88 | 2024-2025 | Vyvgart Hytrulo |
| Merz Pharmaceuticals, LLC | $36.95 | 2025 | Xeomin, Inbrija, Ampyra |
| Xeris Pharmaceuticals, INC. | $36.68 | 2023 | Keveyis |
| Biocodex, INC. | $30.02 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $24.07 | 2021 | |
| Axsome Therapeutics, INC. | $18.23 | 2025 | Symbravo |
| Averitas Pharma INC. | $16.40 | 2023 | Qutenza |
| Tg Therapeutics, INC. | $15.86 | 2024 | |
| Aprecia Pharmaceuticals, LLC | $13.85 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.21 | 2024 | Andexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabrielle Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.